Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EPS (Basic) (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EPS (Basic) for 4 consecutive years, with -$0.66 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 85.81% to -$0.66 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.92, a 102.58% increase, with the full-year FY2024 number at -$18.55, up 68.65% from a year prior.
  • EPS (Basic) was -$0.66 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$1.25 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $9.13 in Q3 2023 to a low of -$50.34 in Q4 2023.
  • A 4-year average of -$5.96 and a median of -$1.02 in 2022 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 1596.72% in 2023; the steepest drop was 7195.65% in 2023.
  • 60 Degrees Pharmaceuticals' EPS (Basic) stood at -$0.69 in 2022, then tumbled by 7195.65% to -$50.34 in 2023, then skyrocketed by 110.71% to $5.39 in 2024, then tumbled by 112.24% to -$0.66 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EPS (Basic) are -$0.66 (Q3 2025), -$1.25 (Q2 2025), and -$1.56 (Q1 2025).